The US updated evidence-based recommendations provide clinicians with comprehensive guidance on when to initiate pharmacologic migraine prevention, how to select an appropriate preventive medication, and how to monitor treatment effectiveness, adverse effects, and medication discontinuation in adults. Developed by a multidisciplinary panel using a systematic review of studies published through June 6, 2024, the guideline integrates evidence from the systematic review, related evidence, principles of care, and evidence-based inferences. The recommendations also address medication selection in specific clinical situations and populations, including patients with fibromyalgia, obesity, or hypertension; older adults; pregnant or lactating patients; sex-related considerations in medication choice; and patients with medication overuse, providing an updated framework for individualized pharmacologic migraine prevention. Source: https://www.neurology.org/
A meta-analysis of 15 randomized controlled trials involving 4,824 patients with high blood pressure found…
Higher levels of chronic systemic inflammation were associated with smaller left ventricular volumes, compensatory increases…
In patients with severe asymptomatic carotid artery stenosis, carotid revascularization—either carotid artery stenting (CAS) or…
A 2026 Cochrane systematic review and meta-analysis of 107 randomized trials involving 26,886 adults with…
Higher functional-connectivity-derived brain age deviation was consistently associated with poorer cognitive performance—particularly working memory and…
Higher nighttime light exposure was associated with adverse changes in cardiac structure and function and…
This website uses cookies.